Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability. Can Urol Assoc J 2013;7(5-6):176-8
Date
10/17/2012Pubmed ID
23069697Pubmed Central ID
PMC3699077DOI
10.5489/cuaj.11251Scopus ID
2-s2.0-84894033230 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
INTRODUCTION: Patients may fail oral overactive bladder therapies due to either poor drug efficacy or intolerability. We determined if the success of sacral neuromodulation varies if performed secondary to lack of anticholinergic efficacy versus drug intolerability.
METHODS: A retrospective review was performed on 152 patients undergoing staged sacral neuromodulation from 2004 to 2010 for refractory idiopathic detrusor overactivity with or without urge incontinence. Outcomes following sacral neuromodulation trials were compared based on the primary indication for anticholinergic failure: lack of drug efficacy versus intolerable side effects.
RESULTS: Overall, successful sacral neuromodulation trials were reported in 70% (106/152) of patients. Successful outcomes were noted in 70% (89/128) and 71% (17/24) of patients with poor anti-cholinergic efficacy and drug intolerability, respectively (p = NS).
CONCLUSIONS: We found no significant difference in outcome success in patients undergoing sacral neuromodulation trials for refractory detrusor overactivity due to lack of anticholinergic efficacy versus intolerability.
Author List
Davis T, Makovey I, Guralnick ML, O'Connor RCAuthors
Michael Guralnick MD Professor in the Urology department at Medical College of WisconsinRobert Corey O'Connor MD Professor in the Urology department at Medical College of Wisconsin
